FY2027 Earnings Forecast for DVAX Issued By William Blair

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - William Blair issued their FY2027 EPS estimates for Dynavax Technologies in a note issued to investors on Wednesday, June 4th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will post earnings of $0.99 per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share.

A number of other equities research analysts have also recently commented on the stock. JMP Securities reduced their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. Wall Street Zen downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Stock Up 0.4%

Shares of NASDAQ:DVAX traded up $0.04 during trading on Friday, hitting $10.28. The company's stock had a trading volume of 1,369,139 shares, compared to its average volume of 2,201,086. The company has a market capitalization of $1.23 billion, a PE ratio of 57.11 and a beta of 1.06. The business has a 50 day moving average price of $10.61 and a two-hundred day moving average price of $12.22. Dynavax Technologies has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The company had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Hedge Funds Weigh In On Dynavax Technologies

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies during the 1st quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd increased its position in Dynavax Technologies by 5,485.7% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,304 shares in the last quarter. Smartleaf Asset Management LLC increased its position in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 2,034 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at $35,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.